Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
NCT06191042Phase 1Completed
- Sponsor
- selectION, Inc.
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Psoriasis vulgaris (PV) and psoriatic arthritis (PsA) comparing si-544 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of si-544. Started Jan 2024; status: completed.
02
Drugs
si-544
03
Conditions
Psoriasis vulgaris (PV)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06191042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191042.